Henry McCusker's  Instablog

Henry McCusker
Send Message
Analyst, Journalist and Publisher ... Henry enters his tenth (10) year at Scimitar Equity -Regenerative Medicine Investors which aggregates, curates and creates bottom-line content weeding of regenerative medicine and cell therapy news to provide a customized, vetted selection of relevant and... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
  • Sangamo Biosciences (SGMO) HIV Therapy Findings 1 comment
    Mar 1, 2011 2:02 PM
    SGMO’s experimental gene/cell therapy was used safely in 6 patients infected with HIV in the first trial of a new approach aimed at blocking the virus so patients won’t need antiviral drugs.

    Findings from the trial were presented 2/28/11 in Boston at the Conference on Retroviruses and Opportunistic Infections, a meeting of infectious disease doctors.

    • After a year, 5 of the 6 had “significant and largely sustained” increases in the number of infection-fighting t- cells in their system. The patients kept taking drugs to suppress the virus during the study because the research first must assess whether the therapy is safe;
    • The treatment modifies patient’s t-cells to inactivate a protein called CCR5 that HIV uses to enter the cells;
    • The theory is that without the entry point, HIV won’t be able to weaken the immune system and patients won’t get sick. If the therapy cuts HIV levels in patients who aren’t taking antiviral drugs, it may gain approval by late 2013. Big … if!

    SGMO is best known for its zinc finger technology that mediates genes, said its cell therapy, called SB-728, and targets a patient’s own CCR5 gene by removing, essentially, the doorknob that HIV turns to gain access to infection-fighting white blood cells. (HWM and RLeuty)

    The Bottom Line: When that data comes at the end of this year, we should have an idea whether the efficacy is durable enough and potent enough. However, any potential side effects aren’t yet fully known! SB-728 is a “functional cure” that creates an army of cells that can mount a response to the virus. It has possible drawbacks: it is a cell therapy to be given in a doctor’s office, rather than patients simply popping antiretroviral pills like those offered by Gilead Sciences. SGMO closed down $0.23 to $8.27 or (-2.71%).

Back To Henry McCusker's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • mpuli
    , contributor
    Comment (1) | Send Message
    when its going to be available to the public
    2 Mar 2011, 07:17 AM Reply Like
Full index of posts »
Latest Followers


  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.